Health Care & Life Sciences » Biotechnology | ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
50.40
47.70
36.20
75.10
47.80
Gross Income
50.40
47.70
36.20
75.10
47.80
SG&A Expense
9,409.90
9,810.90
15,476.90
24,037.00
18,756.30
EBIT
9,460.30
9,858.50
15,513.10
24,112.10
18,804.00
Unusual Expense
642.40
529.80
2,925.30
3,812.40
5,370.00
Non Operating Income/Expense
-
62.70
-
-
-
Interest Expense
-
-
222.80
1,810.40
882.70
Pretax Income
8,800.60
9,377.50
12,790.80
22,085.70
14,312.00
Consolidated Net Income
8,800.60
9,377.50
12,790.80
22,085.70
14,353.80
Net Income
8,800.60
9,377.50
12,790.80
22,085.70
14,353.80
Net Income After Extraordinaries
8,800.60
9,377.50
12,790.80
22,085.70
14,353.80
Net Income Available to Common
8,800.60
9,377.50
12,790.80
22,085.70
17,681.70
EPS (Basic)
6.49
6.26
6.00
7.89
1.23
Basic Shares Outstanding
1,357.00
1,497.90
2,180.10
2,798.90
14,404.30
EPS (Diluted)
6.49
6.26
5.87
7.89
1.23
Diluted Shares Outstanding
1,357.00
1,497.90
2,180.10
2,798.90
14,404.30
EBITDA
9,409.90
9,810.90
15,476.90
24,037.00
18,756.30
Non-Operating Interest Income
17.30
13.90
19.90
24.40
4.70
Other After Tax Income (Expense)
-
-
-
-
41.80
Preferred Dividends
-
-
-
-
3,327.90

About ImmunoCellular Therapeutics

View Profile
Address
30721 Russell Ranch Road
Westlake Village California 91362
United States
Employees -
Website http://www.imuc.com
Updated 07/08/2019
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.